N/A N=10 Basic Science

Ketone Production With Acute Caffeine Intake

Healthy Adults

Bottom Line

View on ClinicalTrials.gov: NCT02694601 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2018

Primary outcome: Primary: Plasma Acetoacetate Concentrations — 26.06; 30.99; 32.10 µmol/L

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Control (Dietary_supplement); Caffeine low dose (Dietary_supplement); Caffeine high dose (Dietary_supplement)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Université de Sherbrooke
Primary completion: Jan 2015

Outcome Measures

Outcome	Result	p-value
PRIMARY Plasma Acetoacetate Concentrations	26.06; 30.99; 32.10	—
PRIMARY Plasma Beta-hydroxybutyrate Concentrations	92.69; 127.57; 144.99	—
SECONDARY Plasma Glucose Concentrations	4.95; 4.96; 4.98	—
SECONDARY Plasma Cholesterol Concentrations	4.26; 4.76; 4.81	—
SECONDARY Plasma Triglyceride Concentrations	0.90; 0.92; 0.97	—

Summary

Evaluate the effect of a caffeine supplement on the stimulation of lipolysis and the production of ketones in healthy adults (N=10).

Eligibility Criteria

Inclusion Criteria

Healthy adults
18 years old and over

Exclusion Criteria

Drinking more than 300 mg of caffeine per day
Diabetes or prediabetes
Abnormal liver and kidney function
Uncontrolled dyslipidemia, blood pressure
Use of drugs known to influence the metabolism of lipids and carbohydrates (steroid, beta-blockers, diuretics, insulin sensitizer, etc.)
Severe inflammation or infection
Pregnancy
Smoking

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02694601). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.